Reply to: "HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study"

Ioanna Markaki^{1

2}, Theodora Ntetsika^{1

2}, Per Svenningsson^{1

2

3}

Affiliations

¹ Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
² Center of Neurology, Academic Specialist Center, Stockholm, Sweden.
³ Neurology Department, Karolinska University Hospital, Huddinge, Sweden.

Comment

Ioanna Markaki et al. Mov Disord. 2021 Aug.

. 2021 Aug;36(8):1993.

doi: 10.1002/mds.28676.

Ioanna Markaki^{1

2}, Theodora Ntetsika^{1

2}, Per Svenningsson^{1

2

3}

¹ Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
² Center of Neurology, Academic Specialist Center, Stockholm, Sweden.
³ Neurology Department, Karolinska University Hospital, Huddinge, Sweden.

No abstract available

Comment on

Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.
Markaki I, Ntetsika T, Sorjonen K, Svenningsson P; BioPark Study Group. Markaki I, et al. Mov Disord. 2021 Jun;36(6):1430-1434. doi: 10.1002/mds.28545. Epub 2021 Feb 26. Mov Disord. 2021. PMID: 33634916
HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study.
Zittel S, Uyar M, Lezius S, Gerloff C, Choe CU. Zittel S, et al. Mov Disord. 2021 Aug;36(8):1991-1992. doi: 10.1002/mds.28689. Mov Disord. 2021. PMID: 34409685 No abstract available.

1. Zittel S, Uyar M, Lezius S, Gerloff C, Choe C. HbA1c and motor outcome in Parkinson's disease in the Mark-PD study. Mov Disord 2021.
1. Markaki I, Ntetsika T, Sorjonen K, Svenningsson P, BioPark Study G. Euglycemia indicates favorable motor outcome in Parkinson's disease. Mov Disord 2021.
1. Brauer R, Wei L, Ma T, et al. Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes. Brain 2020;143(10):3067-3076.
1. Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017;390(10103):1664-1675.
1. Evans JR, Barker RA. Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease. Expert Opin Pharmacother 2011;12(8):1249-1258.